Key Factors to Evaluate Before Investing in Ryan Specialty (RYAN)

By Tamara Parker • Tuesday, June 30 16:00 • Permanent Link

Ryan Specialty sank -3.4% today, compared to the S&P 500's day change of 1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

Ryan Specialty has moved -42.1% over the last year, and the S&P 500 logged a change of 20.0%
RYAN has an average analyst rating of buy and is -11.01% away from its mean target price of $42.47 per share
Its trailing earnings per share (EPS) is $0.82
Ryan Specialty has a trailing 12 month Price to Earnings (P/E) ratio of 46.1 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $2.35 and its forward P/E ratio is 16.1
The company has a Price to Book (P/B) ratio of 7.66 in contrast to the S&P 500's average ratio of 4.74
Ryan Specialty is part of the Finance sector, which has an average P/E ratio of 15.92 and an average P/B of 1.78
The company has a free cash flow of $594.97 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Ryan Specialty Holdings, Inc. operates as a service provider of specialty products and solutions for insurance brokers, agents, and carriers in the United States, Canada, the United Kingdom, rest of Europe, India, Singapore, and internationally. The company offers distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter or a program administrator with delegated authority from insurance carriers. It serves commercial, industrial, institutional, individual, and government sectors. The company was founded in 2010 and is headquartered in Chicago, Illinois.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.